Regulation of TFIIIB during F9 cell differentiation
© Athineos et al; licensee BioMed Central Ltd. 2010
Received: 23 June 2009
Accepted: 12 March 2010
Published: 12 March 2010
Skip to main content
© Athineos et al; licensee BioMed Central Ltd. 2010
Received: 23 June 2009
Accepted: 12 March 2010
Published: 12 March 2010
Differentiation of F9 embryonal carcinoma (EC) cells into parietal endoderm (PE) provides a tractable model system for studying molecular events during early and inaccessible stages of murine development. PE formation is accompanied by extensive changes in gene expression both in vivo and in culture. One of the most dramatic is the ~10-fold decrease in transcriptional output by RNA polymerase (pol) III. This has been attributed to changes in activity of TFIIIB, a factor that is necessary and sufficient to recruit pol III to promoters. The goal of this study was to identify molecular changes that can account for the low activity of TFIIIB following F9 cell differentiation.
Three essential subunits of TFIIIB decrease in abundance as F9 cells differentiate; these are Brf1 and Bdp1, which are pol III-specific, and TBP, which is also used by pols I and II. The decreased levels of Brf1 and Bdp1 proteins can be explained by reduced expression of the corresponding mRNAs. However, this is not the case for TBP, which is regulated post-transcriptionally. In proliferating cells, pol III transcription is stimulated by the proto-oncogene product c-Myc and the mitogen-activated protein kinase Erk, both of which bind to TFIIIB. However, c-Myc levels fall during differentiation and Erk becomes inactive through dephosphorylation. The diminished abundance of TFIIIB is therefore likely to be compounded by changes to these positive regulators that are required for its full activity. In addition, PE cells have elevated levels of the retinoblastoma protein RB, which is known to bind and repress TFIIIB.
The low activity of TFIIIB in PE can be attributed to a combination of changes, any one of which could be sufficient to inhibit pol III transcription. Declining levels of essential TFIIIB subunits and of activators that are required for maximal TFIIIB activity are accompanied by an increase in a potent repressor of TFIIIB. These events provide fail-safe guarantees to ensure that pol III output is appropriate to the diminished metabolic requirements of terminally differentiated cells.
Differentiation of F9 embryonal carcinoma (EC) cells into parietal endoderm (PE) is accompanied by dramatic changes in gene expression. Amongst these are a marked decrease in transcription of tRNA and 5S rRNA genes by pol III, which reflects a reduced requirement for biosynthesis as the differentiating cells stop growing and dividing . Biochemical reconstitution experiments suggested that this change is caused by a specific decrease in activity of the essential pol III transcription factor TFIIIB [1, 2]. In support of this, western blot analysis revealed that PE cells express markedly reduced levels of Brf1, a subunit of TFIIIB that binds pol III and brings it to its targets genes . F9 cell differentiation also involves a decrease in the level of the TATA-binding protein TBP, which is another essential subunit of TFIIIB [2, 3]. However, the conclusion that pol III transcription is regulated under these circumstances through changes in TFIIIB proved to be controversial. Meissner and colleagues argued that TFIIIB activity is unchanged during differentiation and that transcriptional control reflects other mechanisms [4, 5]. They subsequently implcated Bdp1, a third essential subunit of TFIIIB . Here we compare directly the behaviour of the TFIIIB components Brf1, TBP and Bdp1, which had not been done in any of the previous studies. We confirm that each is down-regulated when F9 cells differentiate. Whereas TBP is subject to post-transcriptional control, the fall in Brf1 and Bdp1 levels reflects changes in the corresponding mRNAs. We show that transcriptional repression occurs even if Brf1 expression is maintained in PE cells. We also document changes to several regulators that are known to act directly on TFIIIB.
The fact that HA-Brf1 protein is expressed at unchanged levels in PE cells indicates that the observed decrease in endogenous Brf1 is unlikely to be caused by differential translation or stability. Instead, it suggests that transcription of the endogenous Brf1 gene may be regulated, a mechanism evaded by the CMV promoter that we used to express HA-Brf1. This hypothesis was supported by RT-PCR analysis, which showed that levels of endogenous Brf1 mRNA are lower following differentiation (Fig. 4d). Quantification of four experiments revealed that Brf1 is expressed in PE cells at ~62% of the level observed in undifferentiated EC cells, after normalization to ARPP P0 mRNA. Similarly, the level of Bdp1 mRNA in PE cells is ~46% of that in EC cells, on average. In contrast, TBP mRNA levels are ~72% higher in PE cells relative to EC cells. We conclude that Brf1 and Bdp1 expression is regulated at the mRNA level in differentiating F9 cells. The decrease in Brf1 mRNA expression seen by RT-PCR is less than the decrease seen in Brf1 protein by western immunoblotting. This apparent discrepancy might be explained if Brf1 protein levels respond in a non-linear fashion to the modest decrease in mRNA. In contrast to Brf1 and Bdp1, levels of TBP protein are dictated through post-transcriptional control, as shown by Perletti et al., who demonstrated the selective proteolysis of TBP when F9 cells differentiate .
The activity of TFIIIB in mammals is subject to regulation by a variety of accessory proteins with which it is stably associated [10–12]. These include p53 and the RB family, which inhibit TFIIIB, as well as c-Myc and Erk, which activate TFIIIB. Since each of these regulators can have a profound influence on TFIIIB function, we investigated whether they are also affected by F9 cell differentiation.
Pol III transcription can be stimulated by the proto-oncogene product c-Myc [9, 10, 21, 22]. Recruitment of TFIIIB to target genes is facilitated by c-Myc, an effect that involves the cofactor GCN5 and localised acetylation of histone H3 . We found that expression of c-Myc decreases dramatically when F9 cells differentiate (Fig. 5B), as previously reported [23, 24]. In contrast, little or no change was detected in expression of Max, the dimerisation partner of c-Myc. A second potent activator of TFIIIB is the MAP kinase Erk, which binds and phosphorylates Brf1 . Although the total concentration of Erk protein is relatively constant, its active phosphorylated form is much less prevalent in PE cells (Fig. 5C). Thus, the TFIIIB remaining in these differentiated cells is likely to be deprived of two key regulators that are required for its full activity.
Experiments with crude phosphocellulose fractions provided the first indication that pol III transcription is down-regulated during F9 cell differentiation through inactivation of TFIIIB . At the time, the composition of TFIIIB had not been determined and so molecular reagents were unavailable. The possibility therefore remained that the biochemical activity assays were in fact responding to some alternative factor, present in the same crude fractions. Once the subunits of TFIIIB were identified, regulatory studies could be conducted with a great deal more certainty. The use of specific antibodies allowed demonstration that differentiation of F9 cells is accompanied by a marked decrease in the levels of TBP and Brf1 . This down-regulation of TBP has also been reported independently . Nevertheless, another study suggested that although TFIIIB may become limiting and contribute to the down-regulation of transcription, it cannot account for it . The authors proposed that the key regulatory event that dictates pol III output during differentiation is loss of an activity that they referred to as TFIIIC1 . However, their subsequent analysis revealed that Bdp1 was present in the TFIIIC1 fractions and required for their activity . Indeed, recombinant Bdp1 could substitute for the TFIIIC1 fractions in reconstituting transcription . Western blotting showed a decrease in Bdp1 expression in differentiated F9 cells , a result that we have confirmed here with an alternative antibody and by RT-PCR. Both groups' data therefore support the original model that down-regulation of TFIIIB is responsible for the substantial decrease in pol III transcription that occurs when F9 cells differentiate. Given that the model was based on the use of extremely crude fractions, it is perhaps surprising that it has turned out to be correct.
For most pol III-transcribed genes, including those encoding tRNA and 5S rRNA, the essential components of TFIIIB are TBP, Bdp1 and Brf1 . However, a subset of pol III-dependent genes use a form of TFIIIB in which Brf1 is replaced by its homologue Brf2; these all have upstream (type 3) promoters and include the genes encoding U6, 7SK and Y RNAs. We have not investigated Brf2 in this study.
Specific changes in expression of TBP- associated factors during differentiation are a feature of other transcription systems besides pol III. For example, levels of TAFI48 and TAFI95 decrease when F9 cells differentiate, causing a fall in pol I transcription . The same pair of pol I-specific TAFs are down-regulated during differentiation of B cells into plasma cells . These TAFs are part of the SL1 complex, which is also inactivated when U937 promyelocytic cells differentiate . However, the loss of SL1 activity in U937 cells is not due to changes in the abundance of its constituent TAFs or TBP . The molecular basis of this has not been established, but might reflect loss of c-Myc, which has been shown to bind and activate SL1 . Down-regulated expression of some pol II-specific TAFs has also been observed during differentiation of F9 cells and C2C12 myoblasts [3, 31]. Changes in TAF levels seem therefore to be used in various systems to re-programme gene transcription as cells differentiate.
Expression of the Bdp1 gene is very sensitive to TBP levels, whereas the Brf1 gene is less responsive . The decreased Bdp1 mRNA in F9 PE cells may therefore be a consequence of TBP down-regulation. In contrast, an Erk inhibitor suppresses expression of Brf1, but not Bdp1 . Furthermore, Brf1 expression is stimulated by c-Myc . It is therefore possible that the decrease in Brf1 levels following F9 cell differentiation is caused by the observed regulation of c-Myc and/or Erk. As TBP is down-regulated by selective proteolysis in differentiating F9 cells , we wondered if the same applies to Brf1. However, our data argue strongly against this, since Brf1 protein levels are maintained when the gene is expressed from a constitutive promoter. Regulated proteolytic turnover has not been excluded for Bdp1, but the decrease detected in its mRNA may be sufficient to account for the down-regulation of this TAF.
The fact that forced expression of Brf1 does not restore transcription in PE cells does not mean that Brf1 control is irrelevant in this system. We interpret it as being a reflection of regulatory redundancy, where more than one control mechanism can be sufficient to achieve a phenotypic end point. Indeed, we do not believe that pol III transcription could be restored by reversing any one of the changes that we have documented. Although we have only tested this directly in the case of Brf1, we do not feel it is worth attempting further, as the prospects of success seem remote. Restoring TBP or Bdp1 levels in PE cells is unlikely to have much impact if Brf1 levels become limiting. Co-expressing all three subunits would be difficult to achieve and still would be unlikely to be effective, given the high levels of RB, which is known to bind and repress TFIIIB [13–17]. Depletion of c-Myc is sufficient to inhibit pol III transcription [10, 21, 30, 33]. If c-Myc were introduced into PE cells, its activity would be counteracted by Max-binding repressor proteins, which are induced during differentiation . Furthermore, Erk inhibition is sufficient to suppress pol III transcription [25, 33] and would not be reversed by overexpressing this kinase, as its inactivation in PE cells reflects its dephosphorylation, rather than loss of Erk itself. These considerations have convinced us that attempts to restore TFIIIB activity in PE cells are unlikely to be successful.
F9 EC cells were cultured in Dulbecco's modified eagle medium containing 10% foetal bovine serum, 1 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (all from Sigma). Full differentiation was achieved after 6-7 days by supplementing the medium with 0.1 μM retinoic acid, 1 mM dibutyryl cyclic AMP and 0.1 mM 3-isobutyl-1-methylxanthine (all from Sigma). G418 sulphate (PAA laboratories) was included at a concentration of 500 μg/ml in the medium for stably transfected cells.
Brf1.F9 and Vec.F9 lines were made by transfecting F9 EC cells with pcDNA3.1-HA-HsBrf1  or pcDNA3.1-HA vector (Invitrogen), respectively, using Superfect (Qiagen). After 24 hrs, medium was supplemented with G418 sulphate (500 μg/ml). G418-resistant clones were isolated after four weeks and screened for expression of HA-Brf1 by western blotting with anti-HA antibody F-7 (Santa Cruz Biotechnology Inc).
Transcript expression was assayed by RT-PCR, using published procedures for RNA extraction and reverse transcription . Primers and PCR parameters have been described for Brf1 mRNA , Bdp1 and TBP mRNA , ARPP P0 mRNA , tRNALeu  and tRNAiMet . In vitro transcription assays were conducted with whole cell extracts as previously described .
Protein expression was assayed by western blotting of whole cell extracts, as previously described . Antibodies used were 128 against Brf1 , 2663 against Bdp1 , 4286 against TFIIIC110 , 9102 against Erk and 9106 against activated Erk (both from Cell Signalling Technology), and the following antibodies from Santa Cruz Biotechnology Inc: 58C9 against TBP, IF8 against RB, C-18 against p107, C-20 against p130, N-262 against c-Myc, C-17 against Max, C-18 against TFIIB, A-1 against laminin B1, C-11 against actin and F-7 against the HA tag. Quantification was performed using the TotalLab software from Nonlinear Dynamics, Newcastle, UK and normalized against actin.
acidic ribosomal phosphoprotein
B double prime
This work was funded by Cancer Research UK.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.